Alnylam price target lowered to $265 from $270 at Citi

Citi lowered the firm’s price target on Alnylam to $265 from $270 and keeps a Buy rating on the shares post the Q4 results. The analyst expects continued sales strength in 2023 but notes investors are uncomfortable with the announcement of an FDA panel for Onpattro in ATTR-CM.